Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom

Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom

Abstract Background Characteristics of patients using newer 2nd and 3rd line antidiabetic drugs in a real-world setting are poorly understood. We described the characteristics of new users of sodium-glucose co-transporter-2 inhibitors (SGLT-2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and glucag...

Full description

Bibliographic Details
Main Authors:	Vanessa C. Brunetti, Audray St-Jean, Sophie Dell’Aniello, Anat Fisher, Oriana H. Y. Yu, Shawn C. Bugden, Jean-Marc Daigle, Nianping Hu, Silvia Alessi-Severini, Baiju R. Shah, Paul E. Ronksley, Lisa M. Lix, Pierre Ernst, Kristian B. Filion, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
Format:	Article
Language:	English
Published:	BMC 2022-09-01
Series:	BMC Endocrine Disorders
Subjects:	Type 2 diabetes sodium-glucose co-transporter 2 inhibitors glucagon-like peptide 1 receptor agonists dipeptidyl peptidase 4 inhibitors
Online Access:	https://doi.org/10.1186/s12902-022-01140-1

Similar Items

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
by: Jong Ho Kim, et al.
Published: (2016-04-01)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
by: Naoko Tajima, et al.
Published: (2020-05-01)

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review
by: L. M. Pechmann, et al.
Published: (2024-07-01)

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
by: Song-Chol Mun, et al.
Published: (2020-01-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01)

Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature
by: Yosuke Mai, et al.
Published: (2018-04-01)

The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus
by: Mohammad Sadidi, et al.
Published: (2022-01-01)

Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database
by: Sunghwan Suh, et al.
Published: (2015-06-01)

Acute pancreatitis with gliptins: Is it a clinical reality?
by: Muthukrishnan Jayaraman, et al.
Published: (2013-01-01)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
by: Yumie Takeshita, et al.
Published: (2019-05-01)

Choosing a Gliptin
by: Vishal Gupta, et al.
Published: (2011-01-01)

Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180
by: Yosuke Mai, et al.
Published: (2019-05-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

Association of dipeptidyl peptidase‐4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan
by: Sodai Kubota, et al.
Published: (2023-01-01)

Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
by: Manash P Baruah, et al.
Published: (2016-01-01)

Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy
by: Mohammed Abubaker, et al.
Published: (2017-01-01)

Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario
by: Kiran Shah
Published: (2017-06-01)

Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study
by: Hiroshi Takahashi, et al.
Published: (2019-05-01)

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
by: Vaia Lambadiari, et al.
Published: (2021-02-01)

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
by: Tuchina Taisiia Pavlovna, et al.
Published: (2021-07-01)

Time to exacerbation of heart failure is longer in Malaysian population on dipeptidyl peptidase-4 inhibitor
by: J Hasan, et al.
Published: (2017-01-01)

Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients
by: Young-Hwan Park, et al.
Published: (2024-03-01)

Teneligliptin in management of type 2 diabetes mellitus
by: Sharma SK, et al.
Published: (2016-08-01)

Association of Dipeptidiyl Peptidase-4 Inhibitors and Bullose Pemphigoid: A Report of Four Cases
by: Neslihan USLU, et al.
Published: (2024-06-01)

Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
Published: (2010-09-01)

Reverse phase, ion exchange, HILIC and mix-mode chromatography for the determination of metformin and evogliptin in human plasma and pharmaceutical formulations
by: Pankaj M. Kharabe, et al.
Published: (2024-08-01)

Coumarin Derivatives Act as Novel Inhibitors of Human Dipeptidyl Peptidase III: Combined In Vitro and In Silico Study
by: Dejan Agić, et al.
Published: (2021-06-01)

The effect of dipeptidyl peptidase‐4 inhibitor on incidence and clinical course in bullous pemphigoid patients in a tertiary medical center
by: Yu‐Han Alice Hsu, et al.
Published: (2023-10-01)

Acquired Haemophilia A in DPP4 Inhibitor-induced Bullous Pemphigoid as Immune Reconstitution Syndrome
by: Seiko Sugiyama, et al.
Published: (2020-06-01)

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus
by: Choi YJ, et al.
Published: (2019-08-01)

Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study
by: Shih-Yi Lin, et al.
Published: (2018-06-01)

The Effect of Bioactive Polyphenols from <i>Anacardium occidentale</i> Linn. Leaves on α-Amylase and Dipeptidyl Peptidase IV Activities
by: Nur Imanina Abdullah Thaidi, et al.
Published: (2020-07-01)

Effects of treatment with sitagliptin on hepatotoxicity induced by acetaminophen in mice
by: Wafaa Ahmed Hewedy
Published: (2021-04-01)

A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors
by: Maneesha Khalse, et al.
Published: (2018-01-01)

Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
by: Linong Ji, et al.
Published: (2021-04-01)

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study
by: Linong Ji, et al.
Published: (2021-04-01)

Inhibition of dipeptidyl peptidase IV (DPP-IV) by proline containing casein-derived peptides
by: Alice B. Nongonierma, et al.
Published: (2013-10-01)

Noncardiac pulmonary edema induced by sitagliptin treatment
by: Tahir Belice, et al.
Published: (2014-01-01)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication
by: Yasutake Shinohara, et al.
Published: (2020-10-01)

Association between dipeptidyl peptidase‐4 inhibitors and increased risk for bullous pemphigoid within 3 months from first use: A 5‐year population‐based cohort study using the Japanese National Database
by: Hirohito Kuwata, et al.
Published: (2022-03-01)